At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
In Brief
A Phase 2 clinical trial evaluating Dacarbazine, Laboratory Biomarker Analysis, and 3 other interventions for Iris Melanoma and 5 related conditions. Completed, enrolled 120 participants across 33 sites in 2 countries.
Detailed Summary
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective than selumetinib in treating melanoma of the eye.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Ancillary studies
Given PO
Given PO